Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant). - Wikidata - wikimedia - TriplyDB

Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant).

Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant).

http://www.wikidata.org/entity/Q45918199

about

Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome Update and new approaches in the treatment of Castleman disease Radiotherapy of unicentric mediastinal Castleman's disease Castleman's disease: from basic mechanisms to molecular therapeutics Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib How I treat POEMS syndrome Coexistence of Hodgkin's Lymphoma and Castleman's Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy.POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management.Effective induction therapy with subcutaneous administration of bortezomib for newly diagnosed POEMS syndrome: a case report and a review of the literature.New advances in the diagnosis and treatment of POEMS syndrome.Multicentric Castleman's disease: a challenging diagnosis.Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis.Siltuximab for multicentric Castleman disease.HHV-8-associated multicentric Castleman's disease in HIV-negative patient: a novel therapy for an orphan disease.Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman's disease.Use of a claims database to characterize and estimate the incidence rate for Castleman disease.Successful treatment of POEMS syndrome with bortezomib and dexamethasone, combined with radiotherapy, and followed by autologous stem cell transplantation.TAFRO syndrome: current perspectives.Biologic Agents in the Treatment of Multicentric Castleman Disease

P2860

Q24202634-33F06053-DB73-45AF-A5BC-7A72C9541731 Q26740703-AD92E900-5DE0-46C2-B47F-04F123D08E02 Q33579669-2097170E-C34D-4348-BDED-27EC37FAF09A Q35584575-8889C255-49FB-45BE-866B-E7C32CBB837A Q35979274-30AF1A8F-8192-422D-B9C5-2B3770E35FC0 Q36181433-D3AF2C2A-33D9-4922-949B-3FA8BFB77949 Q37408163-4D931A34-D72D-4656-A4CA-476C4E58B0A7 Q37890982-46090E81-DE04-42E1-BB97-0CF26DFC4B4C Q38061553-5DEBEF1F-3736-41B9-988E-7CDF2C0A0829 Q38080588-A456ECF0-AC44-497C-8D9C-79089E34A3E6 Q38091671-181FC5A6-2D7D-4887-9478-4ACEBE1B2950 Q38167836-2B0A3606-9028-4093-9245-EBDF750E589A Q39146671-A22B8908-F998-4AE8-A6A0-795FBFBC6994 Q43065583-082F11D1-1A20-4EE4-A198-26B37F005719 Q43213062-F5642FA6-07E3-4C6F-9817-2B26685791FE Q43956973-8AF04EF4-35C2-4B3F-BFE5-2695493DCA04 Q45747998-950525AA-A0A8-43D5-BFB4-ABE90C8F09BF Q49384282-DB44BF32-F1C3-4CEC-B08C-981EF5A335D2 Q59137206-EFFB9126-FF03-445D-980F-A0B62E7F8C84

P2860

Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant).

http://www.wikidata.org/entity/Q45918199

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Efficacy of bortezomib in refr ...... syndrome (MCD-POEMS variant).

@en

Efficacy of bortezomib in refr ...... e associated to poems syndrome

@nl

type

label

Efficacy of bortezomib in refr ...... syndrome (MCD-POEMS variant).

@en

Efficacy of bortezomib in refr ...... e associated to poems syndrome

@nl

prefLabel

Efficacy of bortezomib in refr ...... syndrome (MCD-POEMS variant).

@en

Efficacy of bortezomib in refr ...... e associated to poems syndrome

@nl

P1433

Q45918199-9B6EBD3A-C106-4BF7-87B2-85367CA52B98

P1476

Q45918199-524E5652-218C-422C-BCD0-12F1BDF7017A

P2093

Q45918199-02B025C0-119A-4C3B-A94E-9A41DDE1225A

Q45918199-2AEA410C-C7A6-40B3-A915-4ED61B005D86

Q45918199-B02CD754-C1EA-4A5B-A4AF-1B16B5CEC798

Q45918199-D08A99A1-95B9-4777-85CE-6F0EB6038843

Q45918199-D3566644-3340-4BDC-8D23-05FB0B2AFEC8

Q45918199-FFA60A31-C2DE-4274-9209-6DF2993D4D75

P304

Q45918199-E1F8BFFD-723F-4309-B864-A0461A1A7D10

P31

Q45918199-D7193D97-C1C4-4F0D-8BEF-8F64B87B9503

P356

Q45918199-5B20659E-3FAF-48CE-90BE-4BCF4D973969

P433

Q45918199-643A2E1B-9673-4C1A-8D9C-20A7C0AFFF1A

P478

Q45918199-A0F0BF6B-2657-4882-A0DB-315DC7F5C55F

P577

Q45918199-37C4C50F-020B-4924-8A0F-4E9F446D45CC

P5875

Q45918199-89683E80-8B59-4236-ACC8-AEF7EEBCD9BD

P698

Q45918199-A3998ECC-894A-401E-A24C-8425150060A3

P356

S00277-009-0795-6

P1433

Annals of Hematology

P1476

Efficacy of bortezomib in refr ...... syndrome (MCD-POEMS variant).

@en

P2093

Angeles Bendaña Lopez

http://www.w3.org/2001/XMLSchema#string

Jose Diaz Arias

http://www.w3.org/2001/XMLSchema#string

Jose Luis Bello Lopez

http://www.w3.org/2001/XMLSchema#string

Marta Anna Sobas

http://www.w3.org/2001/XMLSchema#string

Maximo Fraga Rodriguez

http://www.w3.org/2001/XMLSchema#string

Natalia Alonso Vence

http://www.w3.org/2001/XMLSchema#string

P304

217-219

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-009-0795-6

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26699561

http://www.w3.org/2001/XMLSchema#string

P698

19636554

http://www.w3.org/2001/XMLSchema#string